Last reviewed · How we verify
Prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness
Approved treatments
- Fragmin · Pfizer Inc.
Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness patent landscape — cliff calendar, originator estates, attackable patents
- Prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness treatment landscape brief
- Prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness treatment updates RSS
Frequently asked questions about Prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness
What drugs treat Prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness?
Tracked treatments include Fragmin.
What is the treatment for Prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness?
Standard treatment for Prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness includes Fragmin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness patent cliff · Prophylaxis of deep vein thrombosis in medical patients with severely restricted mobility during acute illness CI report
- Treatment: Fragmin · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing